Schering AG to partner with NetGenics for gene database

13 June 2001

Schering AG is to partner with the privately-held US informaticscompany NetGenics to build a comprehensive corporate gene database on a worldwide basis.

The database will be used to integrate gene data across the Schering Group, including Schering AG's US subsidiary Berlex Labs, with the aim of providing a single, central point of access to curated and annotated gene, sequence and expression data.

Using proprietary technology from NetGenics' Component Library, such as scientific datamarts, bioinformatics software components and query engines, plus IBM's Discoverylink technology, NetGenics will build a custom gene data integration solution to support collaboration and data sharing, and provide easy access to public and proprietary gene resource databases, says Schering.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight